Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Medicines Co (MDCO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,511,165
  • Shares Outstanding, K 72,640
  • Annual Sales, $ 167,840 K
  • Annual Income, $ -119,120 K
  • 36-Month Beta 0.86
  • Price/Sales 15.10
  • Price/Cash Flow 0.00
  • Price/Book 17.61

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.08 +4.50%
on 09/18/17
39.44 -12.35%
on 10/05/17
+1.41 (+4.25%)
since 09/15/17
3-Month
32.39 +6.73%
on 09/15/17
43.79 -21.06%
on 07/25/17
-3.73 (-9.74%)
since 07/17/17
52-Week
30.80 +12.24%
on 11/03/16
55.95 -38.21%
on 04/11/17
-1.24 (-3.46%)
since 10/17/16

Most Recent Stories

More News
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.05 (+2.17%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.22 (-0.19%)
MDCO : 34.57 (-0.89%)
LLY : 86.06 (+0.13%)
MTZPY : 22.7100 (-0.70%)
BMY : 64.18 (+0.83%)
MKKGY : 22.3800 (-1.62%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.05 (+2.17%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.22 (-0.19%)
MDCO : 34.57 (-0.89%)
LLY : 86.06 (+0.13%)
MTZPY : 22.7100 (-0.70%)
BMY : 64.18 (+0.83%)
MKKGY : 22.3800 (-1.62%)
The Medicines Company to Present New Data from TANGO II Study of VABOMERE(TM) (meropenem and vaborbactam) at IDWeek 2017

---VABOMERE was also associated with better safety and significantly better overall risk-benefit than best available therapy-

MDCO : 34.57 (-0.89%)
The Medicines Company to Present Data at IDWeek 2017 on Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE(TM) (meropenem and vaborbactam)

--- VABOMERE was recently approved for the treatment of adult patients with complicated urinary tract infections, including polynephritis, caused by designated susceptible enterobacteriacea -

MDCO : 34.57 (-0.89%)
The Medicines Co. Continues to Focus on Pipeline Development

The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.

MDCO : 34.57 (-0.89%)
MNK : 32.36 (+0.25%)
REGN : 442.56 (-0.70%)
ALXN : 143.16 (+1.65%)
Shares of Supernus Pharmac Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (SUPN, MDCO, ZGNX, NKTR, TTPH)

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

SUPN : 41.05 (-0.36%)
MDCO : 34.57 (-0.89%)
ZGNX : 38.10 (-1.17%)
NKTR : 23.99 (+1.35%)
TTPH : 6.47 (-2.56%)
Corporate News Blog - FDA Grants Approval to The Medicines Co.'s VABOMERE(TM)

Research Desk Line-up: SteadyMed Post Earnings Coverage

STDY : 3.15 (-1.56%)
MDCO : 34.57 (-0.89%)
The Medicines Company's Infection Drug Vabomere Gets FDA Nod

The Medicines Company's (MDCO) infection-resistant antibiotic Vabomere secures a fast FDA approval for urinary tract diseases. The drug is likely to hit the market in fourth-quarter 2017.

MDCO : 34.57 (-0.89%)
ACAD : 36.99 (+2.47%)
PFE : 36.20 (+0.61%)
ADRO : 9.65 (+1.58%)
Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update

It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.

MDCO : 34.57 (-0.89%)
VRTX : 155.05 (+0.23%)
BMRN : 93.54 (-1.18%)
INCY : 115.64 (-0.82%)
GILD : 80.24 (+0.36%)
ACOR : 26.65 (+2.30%)
KITE : 179.99 (+0.11%)
The Medicines Company Announces FDA Approval of VABOMERE(TM) (meropenem and vaborbactam)

---First carbapenem-based combination product - combination of meropenem with a new class of beta-lactamase inhibitor-

MDCO : 34.57 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment ofpatients with unstable angina undergoing coronary balloon angioplasty. The company...

See More

Support & Resistance

2nd Resistance Point 35.32
1st Resistance Point 34.94
Last Price 34.57
1st Support Level 34.30
2nd Support Level 34.04

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart